Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
Giovany Orozco-LealEugenie Evelynne JohnsonSedighe HosseinijebeliTomos RobinsonTara HomerClaire H EastaughCatherine RichmondLouise TannerNick MeaderRyan P W KennySheila A WallaceStephen RicePublished in: PharmacoEconomics (2023)